BioTechnology, established on 2015, devoted its activities to one of the crucial challengers of the XXI century - the study of oncological diseases and the development of drugs that can treat cancer.
According to the forecast of the International Agency for Research on Cancer (IARC WHO), by 2035, the incidence of malignant neoplasms will increase by 42% and amount to 27.4 million new cases per year. One of the directions of development of antitumor therapy is the creation of nanosomal drug delivery systems (NDDS). The National Cancer Institute of the USA (NSI US) has been implementing a program to support the development of nanosomal drugs in oncology"Cancer Nanotechnology plan" since 2004. There are similar programs in the European Union and Japan. The creation of innovative drugs for the treatment of oncological diseases (including those based on NDS technologies) is an important part of the development strategy of the pharmaceutical industry.
According to the forecast of the International Agency for Research on Cancer (IARC WHO), by 2035, the incidence of malignant neoplasms will increase by 42% and amount to 27.4 million new cases per year. One of the directions of development of antitumor therapy is the creation of nanosomal drug delivery systems (NDDS). The National Cancer Institute of the USA (NSI US) has been implementing a program to support the development of nanosomal drugs in oncology"Cancer Nanotechnology plan" since 2004. There are similar programs in the European Union and Japan. The creation of innovative drugs for the treatment of oncological diseases (including those based on NDS technologies) is an important part of the development strategy of the pharmaceutical industry.
Our Team
- Vologodsky Andrey NikolaevichGeneral Manager
- Matyunina Ekaterina AleksandrovnaHead of Research Development and Planning DepartmentSt. Petersburg State University, majoring in biochemistry, leading researcher at Biotechnology LLC.
He has extensive experience in solving various biotechnological problems, introducing new applied molecular biological areas, and planning experimental studies.. - Aleshkin Andrey VladimirovichDoctor of Biological SciencesHead of the Laboratory of Clinical Microbiology and Biotechnology of Bacteriophages, Moscow Research Institute of Epidemiology and Microbiology named after. G.N. Gabrichevsky Rospotrebnadzor, professor of the department of clinical microbiology and phage therapy of Moscow State Medical University named after. A.I. Evdokimov.A second-generation specialist in the field of bacteriophages, he has extensive experience and leads a whole staff of scientists engaged in basic research aimed at introducing bacteriophages to treat various diseases.
- Kolesanova Ekaterina FedorovnaDoctor of biological sciences
Head of the Laboratory of Peptide Synthesis at the Research Institute of Biomedical Chemistry named after V.N. Orekhovich" - Sivov Igor GennadievichLead product and patent developer
State Research Institute "Bioeffect", LLC "Medsintez" - Grigorieva Elena YurievnaHead of the Laboratory of Radionuclide and Radiation Technologies in Experimental Oncology, Research Institute of Clinical and Experimental Radiology.
Our Contacts
Ask your question or you can call us
in a phone number below
in a phone number below
+7 (916) 107-06-61
projects@pefagtal.com
projects@pefagtal.com
121069, г. Москва, вн. тер. муниципальный округ Арбат, бульвар Новинский, д. 18, корп. 2, помещ. 1/1
Tashkent,Uzbekistan branch of BioTechnology
Kichik Beshagach st., 27, Tashkent, Uzbekistan
Tashkent,Uzbekistan branch of BioTechnology
Kichik Beshagach st., 27, Tashkent, Uzbekistan